

Fiscal quarter ended June 2008 – supplementary financial summary –

August 6, 2008 Asahi Kasei Corporation

Contents

Asahi KASEI

Consolidated results for fiscal quarter ended June 2008	Forecast for first fiscal half 2008
Summary of financial results4	Consolidated operating performance12
Statements of income5	Forecast by segment13–14
Balance sheets6	Appendix
Cash flows7	Overview of results by segment16–23

Sales and operating profit by segment 8–10



Consolidated results for fiscal quarter ended June 2008

Summary of financial results

Asahi **KASEI**

(¥ hillion)

						(± UIII0II)	
	April–June 2007	April–June April–Sept. April–June 2008 forecast 2007 y		nt Anri-lune i i i		–June s. 2008	
	2007	2007	2008 a	in May b	Increase (decrease)	% change	a/b
Net sales	385.2	830.8	386.0	856.0	0.8	+0.2	45.1%
Operating profit	25.9	63.7	19.4	50.5	(6.5)	-25.1	38.4%
Ordinary profit	28.2	63.1	21.2	49.5	(7.0)	-24.7	42.9%
Net income	18.1	38.0	13.5	30.0	(4.6)	-25.5	44.9%

Key operating factors

Naphtha price (¥/kL, domestic)	57,800	58,750	70,900	68,000
¥/US\$ exchange rate (market average)	121	119	105	105

Financial position

	At end of March 2008	At end of June 2008	Increase (decrease)
Total assets	1,425.4	1,480.5	55.1
Equity	666.2	666.9	0.7
Interest-bearing debt	211.4	259.3	47.9
Debt/equity ratio	0.32	0.39	0.07

Statements of income

Asahi **KASEI**

						(¥ billion)
	April–Ju	ne 2007	April–Ju	ne 2008	Increase	% change
		% of sales		% of sales	(decrease)	70 change
Net sales	385.2	100.0%	386.0	100.0%	0.8	+0.2
Cost of sales	291.0	75.6%	295.6	76.6%	4.6	+1.6
Gross profit	94.1	24.4%	90.4	23.4%	(3.8)	-4.0
Selling, general and administrative expenses	68.2	17.7%	71.0	18.4%	2.8	+4.0
Operating profit	25.9	6.7%	19.4	5.0%	(6.5)	-25.1
Non-operating expenses	2.3		1.8		(0.5)	
of which,						
financing income and expense	0.9		0.6		(0.3)	
equity in net earnings of unconsolidated subsidiaries and affiliates	1.0		0.4		(0.6)	
Ordinary profit	28.2	7.3%	21.2	5.5%	(7.0)	-24.7
Special gains and losses	(0.4)		(0.6)		(0.2)	
Income before income taxes and minority interest	27.9	7.2%	20.7	5.4%	(7.2)	-25.8
Income taxes	(9.7)		(6.9)		2.7	
Minority interest in income of consolidated subsidiaries	(0.1)		(0.3)		(0.1)	
Net income	18.1	4.7%	13.5	3.5%	(4.6)	-25.5
	•					5/

5/24

Asahi **KASEI**

							(¥ billion)
	At end of Mar. 2008	At end of Jun. 2008	Increase (decrease)		At end of Mar. 2008	At end of Jun. 2008	Increase (decrease)
Current assets	740.1	767.1	27.0	Liabilities	751.2	805.7	54.5
Cash on hand and in banks	82.9	84.7	1.8	Current liabilities	513.4	582.5	69.1
Notes and accounts receivable, trade	298.8	296.4	(2.4)	Long-term liabilities	237.8	223.3	(14.5)
Inventories	272.4	296.5	24.2	Net assets	674.2	674.7	0.6
Other current assets	86.0	89.5	3.4	Shareholders' equity	613.0	617.6	4.5
Fixed assets	685.3	713.4	28.1	Common stock	103.4	103.4	_
Property, plant and equipment	424.2	429.0	4.9	Capital surplus	79.4	79.4	0.0
Intangible fixed assets	26.2	37.6	11.4	Retained earnings	432.2	436.8	4.5
Investments and other	234.9	246.8	11.9	Treasury stock, at cost	(2.0)	(2.1)	(0.0)
assets				Valuation, translation adjustments and others	53.2	49.4	(3.8)
				Minority interest in consolidated subsidiaries	7.9	7.8	(0.1)
Total assets	1,425.4	1,480.5	55.1	Total liabilities and net assets	1,425.4	1,480.5	55.1

Asahi KASEI

(¥ billion)

		Q1 2007	Q1 2008
a.	Cash flows from operating activities	(10.7)	4.8
b.	Cash flows from investing activities	(14.4)	(40.5)
c.	Free cash flows [a+b]	(25.1)	(35.7)
d.	Cash flows from financing activities	(15.1)	40.3
e.	Effect of exchange rate changes on cash and cash equivalents	(0.0)	(2.8)
f.	Net decrease in cash and cash equivalents [c+d+e]	(40.2)	1.7
g.	Cash and cash equivalents at beginning of year	101.7	83.0
h.	Cash and cash equivalents held by newly consolidated subsidiaries	_	_
I.	Cash and cash equivalents at end of year [f+g+h]	61.5	84.8

Sales and operating profit by segment

Asahi KASEI

(¥ billion)

		Sales		O	perating pro	fit
	Q1 2007	Q1 2008	Increase (decrease)	Q1 2007	Q1 2008	Increase (decrease)
Chemicals	218.1	210.4	(7.7)	17.2	9.1	(8.1)
Homes	62.3	63.7	1.4	(2.8)	(3.7)	(0.9)
Pharma	27.2	34.6	7.4	4.6	9.0	4.4
Fibers	28.2	26.7	(1.5)	1.7	1.2	(0.5)
Electronics Materials & Devices	29.2	28.2	(1.1)	5.8	4.5	(1.2)
Construction Materials	15.2	14.7	(0.6)	1.1	0.3	(0.7)
Services, Engineering and Others	4.8	7.7	2.9	0.4	1.3	0.9
Corporate Expenses and Eliminations	_	_	_	(2.0)	(2.3)	(0.3)
Consolidated	385.2	386.0	0.8	25.9	19.4	(6.5)

Sales increases/decreases by segment AsahiKASEI

(Q1 2007 vs. Q1 2008, ¥ billion)

	Sa	les	I	ncrease (decrease) due t	0:	
	Q1 2007	Q1 2008	Sales volume	Sales prices	of which, due to foreign exchange	Others	Net increase (decrease)
Chemicals	218.1	210.4	(5.2)	5.5	(6.1)	(8.0)	(7.7)
Homes	62.3	63.7	(0.8)	0.5	_	1.7	1.4
Pharma	27.2	34.6	3.3	(1.9)	(0.2)	6.0	7.4
Fibers	28.2	26.7	(1.9)	0.4	(0.3)	0.0	(1.5)
Electronics Materials & Devices	29.2	28.2	0.8	(1.6)	(1.2)	(0.3)	(1.1)
Construction Materials	15.2	14.7	(0.6)	0.1	_	0.0	(0.6)
Services, Engineering and Others	4.8	7.7	2.9	0.0	0.0	0.0	2.9
Total	385.2	386.0	(1.5)	2.9	(7.8)	(0.6)	0.8

Operating profit increases/decreases by segmentAsahiKASEI

(Q1 2007 vs. Q1 2008, ¥ billion)

	Operatir	ng profit	Ι	ncrease (decrease) due t		
	Q1 2007	Q1 2008	Sales volume	Sales prices	of which, due to foreign exchange	Operating costs and others	Net increase (decrease)
Chemicals	17.2	9.1	(1.4)	5.5	(6.1)	(12.2)	(8.1)
Homes	(2.8)	(3.7)	(0.9)	0.5	_	(0.6)	(0.9)
Pharma	4.6	9.0	2.3	(1.9)	(0.2)	4.0	4.4
Fibers	1.7	1.2	0.0	0.4	(0.3)	(0.9)	(0.5)
Electronics Materials & Devices	5.8	4.5	0.5	(1.6)	(1.2)	(0.2)	(1.2)
Construction Materials	1.1	0.3	(0.2)	0.1	_	(0.6)	(0.7)
Services, Engineering and Others	0.4	1.3	1.0	0.0	0.0	(0.0)	0.9
Corporate Expenses and Eliminations	(2.0)	(2.3)	_	_	_	(0.3)	(0.3)
Total	25.9	19.4	1.4	2.9	(7.8)	(10.8)	(6.5)



Forecast for first fiscal half 2008

Consolidated operating performance



(¥ billion)

		FY 2007	_	H1	2008 for	recast	Increase (decrease)	FY 2008 forecast in May		Increase (decrease)
	H1	H2	Total	Q1	Q2		(ucereuse)	H1	Total	(accrease)
	а				forecast	b	b-a	с		b-c
Net sales	830.8	866.0	1,696.8	386.0	472.0	858.0	27.2	856.0	1,810.0	2.0
Operating profit	63.7	64.0	127.7	19.4	18.6	38.0	(25.7)	50.5	128.0	(12.5)
Ordinary profit	63.1	57.3	120.5	21.2	15.8	37.0	(26.1)	49.5	125.0	(12.5)
Net income	38.0	31.9	69.9	13.5	8.5	22.0	(16.0)	30.0	75.0	(8.0)

Key operating factors

Naphtha price (¥/kL, domestic)	58,750	64,150	61,450	70,900	87,000	78,950	20,200	68,000	68,000	10,950
¥/US\$ exchange rate (market average)	119	109	114	105	105	105	(14)	105	105	0

Sales forecast by segment

Asahi **KASEI**

(¥ billion)

	FY 2007			FY 2008			T	H1 200	8
	Q1	Q2	1st half	Q1	Q2 forecast	1st half forecast	Increase (decrease)	forecas in May	(decrease)
Chemicals	218.1	228.3	446.4	210.4	249.6	460.0	13.6	447.0	13.0
Homes	62.3	104.6	166.9	63.7	109.3	173.0	6.1	178.0	(5.0)
Pharma	27.2	27.6	54.9	34.6	28.4	63.0	8.2	63.0) _
Fibers	28.2	28.7	56.9	26.7	29.3	56.0	(0.9)	59.() (3.0)
Electronics Materials & Devices	29.2	28.4	57.7	28.2	29.8	58.0	0.3	61.0) (3.0)
Construction Materials	15.2	14.7	29.9	14.7	15.3	30.0	0.1	31.0) (1.0)
Services, Engineering and Others	4.8	13.2	18.1	7.7	10.3	18.0	(0.1)	17.0	1.0
Consolidated	385.2	445.6	830.8	386.0	472.0	858.0	27.2	856.0	2.0

Operating profit forecast by segment

Asahi **KASEI**


(¥ billion) FY 2007 FY 2008 H1 2008 Increase Increase forecast 1st half **O**2 (decrease) (decrease) 1st half Q1 Q2 Q1 in May forecast forecast Chemicals 36.2 16.5 (19.7)25.5 17.2 19.0 9.1 7.4 (9.0)Homes 4.8 (3.7)3.0 (1.8)5.0 (2.0)(2.8)7.6 6.7 7.7 2.3Pharma 3.1 9.0 1.0 10.0 9.5 0.54.6 **Fibers** 1.8 3.5 1.2 1.5 (2.0)2.5 1.7 0.3 (1.0)**Electronics** Materials 5.8 11.5 5.7 4.5 4.5 9.0 (2.5)9.5 (0.5)& Devices **Construction Materials** 1.1 2.1 0.3 0.2 0.5 (1.6)1.5 1.0 (1.0)Services, Engineering 2.7 2.5 (0.2)2.00.5 1.3 0.4 2.4 1.2 and Others Corporate Expenses (5.0)(0.1)(5.0)(4.9)(2.9)(2.3)(2.7)(2.0)____ and Eliminations 50.5 Consolidated 25.9 37.8 63.7 19.4 18.6 38.0 (25.7)(12.5)



Appendix

Chemicals





erating profit Review of operations

Good performance in specialty products. Strong impact of higher feedstock costs for volume products. Sales and operating profit decrease.

Volume products:

Maintenance turnaround at ethylene center, which was not carried out a year ago. Strong yen and higher feedstock costs. Operating profit decrease.


Specialty products:

Increased sales of Hipore[™] Li-ion rechargeable battery separators and ion-exchange membranes. Operating profit increase.

Highlights

- April, launch of wastewater recycling business; first order received for wastewater recycling service, in Suzhou, China.
- June, start of utilization of wood biomass fuel for power generation.

Homes (i)



Review of operations

Good performance of remodeling business. Decreased deliveries of order-built unit homes. Sales increase, but operating loss increase.

With challenging general climate for housing, value of new orders decreasing 3.0% from the first quarter a year ago.

Results by product category*	Results	by product	category*
------------------------------	---------	------------	-----------

	Q	1 2007	Q	1 2008	Increas	e (decrease)
	Sales	Operating profit	Sales	Operating profit	Sales	Operating profit
Order-built homes	46.6		44.4		(2.2)	
Pre-built homes	0.9		2.6		1.7	
Others	0.1		0.2		0.1	
Total homes	47.6	(4.0)	47.2	(4.9)	(0.4)	(0.9)
Housing- related	14.7	1.2	16.5	1.2	1.8	0.0
Total	62.3	(2.8)	63.7	(3.7)	1.4	(0.9)

* Product category division unaudited.


Sales and order trends

(¥ billion, % change from same period of previous year shown at right)

			new orders the term		of order- homes		of pre-built omes	Other sales*	Unconsolidated	Consolidated subsidiaries	Conse	olidated	Order backlog
FY 04	H1	153.1	(-5.2%)	138.9	(+14.6%)	6.6	(+25.3%)	0.5	146.0 (+15.0%)	21.3 (+1.9%)	167.3	(+13.2%)	333.2
	H2	148.7	(-5.1%)	171.9	(+7.5%)	13.6	(-55.9%)	0.6	186.0 (-2.8%)	22.5 (+0.9%)	208.5	(-2.3%)	310.1
	annual	301.8	(-5.1%)	310.7	(+10.6%)	20.1	(-44.1%)	1.1	332.0 (+4.3%)	43.8 (+1.6%)	375.8	(+4.0%)	
FY05	H1	150.4	(-1.7%)	140.2	(+0.9%)	20.5	(+213.0%)	0.4	161.1 (+10.4%)	24.2 (+13.8%)	185.3	(+10.8%)	320.4
	H2	162.9	(+9.5%)	179.3	(+4.3%)	13.1	(-3.6%)	0.6	193.0 (+3.8%)	26.2 (+16.4%)	219.2	(+5.1%)	304.0
	annual	313.3	(+3.8%)	319.4	(+2.8%)	33.6	(+67.0%)	1.1	354.1 (+6.7%)	50.4 (+15.1%)	404.5	(+7.7%)	
FY 06	H1	156.1	(+3.7%)	134.7	(-3.9%)	6.0	(-70.9%)	0.5	141.1 (-12.4%)	28.0 (+15.2%)	169.1	(-8.7%)	325.3
	H2	147.3	(-9.6%)	182.9	(+2.0%)	23.0	(+75.8%)	0.5	206.4 (+6.9%)	30.2 (+15.7%)	236.6	(+7.9%)	289.8
	annual	303.4	(-3.2%)	317.6	(-0.6%)	28.9	(-13.8%)	1.0	347.5 (-1.9%)	58.2 (+15.5%)	405.7	(+0.3%)	
FY07	Q1	79.6	(-4.9%)	46.6	(+7.1%)	0.9	(-51.3%)	0.1	47.6 (+4.8%)	14.7 (+11.4%)	62.3	(+6.4%)	322.8
	Q2	74.0	(2.4%)	84.6	(-7.3%)	4.1	(-1.8%)	0.3	89.0 (-7.1%)	15.6 (+5.4%)	104.6	(-5.3%)	312.3
	H1	153.6	(-1.5%)	131.2	(-2.6%)	5.0	(-16.5%)	0.4	136.6 (-3.2%)	30.3 (+8.2%)	166.9	(-1.3%)	312.3
	H2	152.5	(+3.5%)	165.9	(-9.3%)	19.5	(-15.1%)	0.5	186.0 (-9.9%)	33.3 (+10.3%)	219.3	(-7.3%)	298.8
	annual	306.1	(+0.9%)	297.1	(-6.5%)	24.5	(-15.4%)	1.0	322.5 (-7.2%)	63.7 (+9.5%)	386.2	(-4.8%)	
FY08	Q1	77.3	(-3.0%)	44.4	(-4.7%)	2.6	(+196.2%)	0.2	47.2 (-0.9%)	16.5 (+12.2%)	63.7	(+2.2%)	331.7
	Q2	76.7	(+3.7%)	86.2	(+1.9%)	4.2	(+2.7%)	0.2	90.7 (+1.9%)	18.7 (+19.7%)	109.3	(+4.5%)	322.2
	H1 forecast	154.0	(0.0%)	130.6	(-0.4%)	6.8	(36.4%)	0.4	137.8 (+0.9%)	35.2 (+16.1%)	173.0	(+3.7%)	

* Including commissions on property insurance.

Pharma (i)



Review of operations

Decline of reimbursement prices for both pharmaceuticals and medical devices. Licensing income for FamvirTM antiviral for herpes zoster. Increased shipments of APSTM polysulfonemembrane artificial kidneys and SepacellTM leukocyte reduction filters. Sales and operating profit increase.

Highlights

- April, establishment of medical device sales subsidiary in Taiwan.
- April, approval acquired for Famvir[™] antiviral for herpes zoster and marketing alliance with Maruho Co., Ltd.; July, NHI price listing.
- April, NHI price listing for Recomodulin[™] recombinant thrombomodulin.
- May, completion of spinning plant for EVOH hollow-fiber membrane; June, start of production.
- June, decision to expand capacity for APSTM polysulfone hollow-fiber dialyzer membrane.
- June, license agreement for exclusive rights in Japan to develop and sell pentosan polysulfate for osteoarthritis.
- July, establishment of new laboratory for joint research linking industry and academia for advanced medical technology.

Pharma (ii)

Sale	les of Asahi Kasei Pharma Corp. (¥ billio							
				FY 20	FY 2008			
				Q1	H1	Q1		
			Pharamaceuticals	12.1	24.1	18.4		
			Others	1.5	2.9	1.1		
		Non-consolidated		13.6	27.0	19.5		
		Devices*		12.4	24.7	13.5		
		Ot	hers	1.2	3.1	1.6		
	С	ons	solidated	27.2	54.9	34.6		

* Asahi Kasei Kuraray Medical and Asahi Kasei Medical.


Main pharmaceuticals domestic sales

(¥ billion)

	FY 20	FY 2008	
	Q1	H1	Q1
Elcitonin TM	3.5	7.1	3.3
Bredinin TM	1.6	3.1	1.6
Flivas TM	2.4	4.7	2.2
Toledomin TM	1.6	3.1	1.5
Exacin TM	0.3	0.5	0.2
Zesulan TM	0.3	0.5	0.3
Eril TM	0.4	0.7	0.4

Fibers






Review of operations

Deterioration of market price for RoicaTM elastic polyurethane filament. Strong impact of rising feedstock and fuel costs for BembergTM regenerated cellulose and nonwovens operations. Sales and operating profit decrease.

Electronics Materials & Devices




Review of operations

Increased volume both for electronics devices and electronics materials. Lower product prices. Strong yen. Sales and operating profit decrease.

Highlights

 June, completion of plant expansion for Sunfort[™] dry film photoresist for printed wiring boards in China and start of production.

Construction Materials



Review of operations

Strong impact from a decline in the number of new construction starts and a sharp rise in feedstock and fuel costs for HebelTM autoclaved lightweight concrete (ALC) panels and NeomaTM high-performance phenolic foam insulation panels. Sales and operating profit decrease.



– Disclaimer –

The forecasts and estimates shown in this document are dependent on a variety of assumptions and economic conditions. Plans and figures depicting the future do not imply a guarantee of actual outcomes.